Stream
Stories
-
Telix registers Phase 3 study of [18F]FET PET in brain metastases
The study, led by Telix Pharmaceuticals (Innovations) Pty Limited, plans to enroll 381 participants and begin in December 2026. It will evaluate whether [18F]Floretyrosine PET can differentiate tumor progression from treatment-related changes in patients with brain metastases and equivocal MRI findings.
-
Qilu Pharmaceutical registers Phase 3 trial of QLS4131 in relapsed or refractory multiple myeloma
The study, first posted on ClinicalTrials.gov on November 12, 2026, plans to enroll 300 participants and has a planned start date of December 30, 2026. It compares QLS4131 injection with the investigator's choice regimen in participants with relapsed or refractory multiple myeloma.
-
AstraZeneca registers Phase III trial of FDC laroprovstat/rosuvastatin in hypercholesterolemia
The study plans to enroll 204 participants and is expected to start on December 21, 2026. It aims to evaluate the effect on LDL-C and the safety and tolerability of the fixed-dose combination in lipid-lowering treatment-naïve patients.
-
Rhythm posts results of Phase 3 setmelanotide trial in genetic obesity
The study enrolled 296 participants and completed primary data collection on December 19, 2025. Results were first posted on ClinicalTrials.gov on November 12, 2026.
-
Hoffmann-La Roche posts results of Phase III obinutuzumab study in systemic lupus erythematosus
Results for the study were first posted on ClinicalTrials.gov on November 12, 2026. The Phase III trial enrolled 303 participants, with primary completion on September 15, 2025, and compared obinutuzumab to placebo in patients with active, autoantibody-positive systemic lupus erythematosus receiving standard-of-care therapy.
-
Pfizer posts results of Phase 3 gene therapy study in Duchenne Muscular Dystrophy
The study, a Phase 3 long-term safety and efficacy follow-up of fordadistrogene movaparvovec, enrolled 7 participants and was terminated. It began on March 13, 2023, with primary completion on September 24, 2025.
-
Argá Medtech completes enrollment of paroxysmal AF cohort in COHERENT-AF
The company announced that 150 intention-to-treat subjects were enrolled in the paroxysmal atrial fibrillation cohort across 27 sites in Europe and the United States. Enrollment of the persistent AF cohort is ongoing and expected to finish in the next two months.
-
Lilly reports 52-week results of Taltz and Zepbound in psoriatic arthritis and obesity
The company said that at one year 43.7% of patients receiving Taltz and Zepbound achieved ACR50 compared with 15.7% for Taltz alone. The 52-week Phase 3b study randomized 271 participants 1:1 to the combination or Taltz monotherapy and reported mild to moderate adverse events consistent with each drug's known safety profile.
-
Zinzino acquires Uzesta to boost distribution capabilities in the APAC region
Zinzino has acquired the rights to Uzesta Global LLC's distributor database, inventory and intellectual property rights through subsidiaries in Taiwan, Hong Kong and Thailand. The deal includes a fixed purchase price of 0.8 mUSD in cash and a deferred price of 0.4 mUSD, with potential additional payments up to 6.0 mUSD based on future sales.
-
Amgen announces positive Phase 3 results for dazodalibep in Sjögren's disease
Amgen said the Phase 3 OASIZ-301 study met its primary endpoint, with both 1,500 mg every four weeks and 3,000 mg every 12 weeks regimens showing statistically significant reductions in ESSDAI score versus placebo at Week 48. The company noted improvements in patient-reported dryness and that the most common adverse events were nasopharyngitis, urinary tract infection, hypertension and infusion-related reactions.
-
Xtalks hosts webinar on using EHR and applied AI to speed patient recruitment
The webinar, scheduled for Wednesday, December 2, 2026 at 10am EST, explores how integrating EHR capabilities with applied AI can improve patient identification and reduce manual record review. Speakers include Mike Margiotta of AiSync, Meagan Garvin of Trialbee, and Carl Wolff of Trialbee.
-
FDA releases draft guidance on early-phase IND protocols for solid tumors
FDA announced the availability of a draft guidance titled "Early-Phase IND Protocol Recommendations for Solid Tumors" to provide recommendations for sponsors and investigators developing early-phase trials. Comments are due by January 11, 2027, and the guidance covers first-in-human protocols for drugs and biologic products with limited human experience, but does not address hematologic malignancies.